Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 9/20 | 1.00 |
| ▸ | ABCC8 | Q09428 | 2/20 | 1.00 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 1.00 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (-)-Cromakalim SCHEMBL12833 | 1.00 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| (-)-Cromakalim SCHEMBL10644663 | 1.00 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Levcromakalim SCHEMBL30059152 | 1.00 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| (-)-Cromakalim SCHEMBL24658941 | 1.00 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Cromakalim SCHEMBL3312760 | 1.00 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| (-)-Cromakalim SCHEMBL25029865 | 1.00 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| (-)-Cromakalim SCHEMBL3771007 | 1.00 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| (-)-Cromakalim SCHEMBL29345689 | 1.00 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Cromakalim SCHEMBL30110320 | 1.00 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL10636063 | 0.97 | ABCC9 (0.94) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1947 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076961-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2026-03-19 | — | — | US | claimed |
| US-12564573-B2 | Topical ocular delivery of cromakalim | QLARIS BIO, INC. (US) | 2026-03-03 | — | — | US | claimed |
| US-12564572-B2 | Topical ocular delivery of cromakalim | QLARIS BIO, INC. (US) | 2026-03-03 | — | — | US | claimed |
| US-20250387366-A1 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | QLARIS BIO, INC. (US) | 2025-12-25 | — | — | US | claimed |
| WO-2025078664-A1 | TREATMENT OF METASTATIC OR INVASIVE BRAIN CANCER | Celex Oncology Innovations Limited (GB) | 2025-04-17 | — | — | WO | claimed |
| US-20250108002-A1 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | QLARIS BIO, INC. (US) | 2025-04-03 | — | — | US | claimed |
| US-20250108035-A1 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | QLARIS BIO, INC. (US) | 2025-04-03 | — | — | US | claimed |
| EP-4486338-A2 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | Qlaris Bio, Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| WO-2024098043-A2 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | QLARIS BIO, INC. (US) | 2024-05-10 | — | — | WO | claimed |
| US-20220347172-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2022-11-03 | — | — | US | claimed |
| US-4738963-A | NITROGEN SUBSTITUTED BENZO(B)PYRAN | BEECHAM GROUP P.L.C. (GB) | 1988-04-19 | — | — | US | claimed |
| WO-1988000822-A1 | METHODS, COMPOSITIONS AND SOLUTIONS FOR TREATING ALOPECIA | THE UPJOHN COMPANY (US) | 1988-02-11 | — | — | WO | claimed |
| US-4719228-A | Pharmaceutical composition | Rawlins, David A. (GB) | 1988-01-12 | — | — | US | claimed |
| EP-0207614-A2 | Benzopyran compounds in the treatment of incontinence | BEECHAM GROUP PLC (GB) | 1987-01-07 | — | — | EP | claimed |
| EP-0076075-B1 | PHARMACEUTICALLY ACTIVE BENZOPYRAN COMPOUNDS | BEECHAM GROUP PLC (GB) | 1986-11-20 | — | — | EP | claimed |
| EP-0176689-A2 | Benzopyran compounds for the treatment of smooth muscles contraction | BEECHAM GROUP PLC (GB) | 1986-04-09 | — | — | EP | claimed |
| EP-0173848-A2 | Benzopyran compounds for use in the cardiovascular system | BEECHAM GROUP PLC (GB) | 1986-03-12 | — | — | EP | claimed |
| EP-0120428-A1 | Benzopyran isomers | BEECHAM GROUP PLC (GB) | 1984-10-03 | — | — | EP | claimed |
| US-4446113-A | HYPOTENSIVE AGENTS | BEECHAM GROUP P.L.C. (GB) | 1984-05-01 | — | — | US | claimed |
| EP-0076075-A1 | Pharmaceutically active benzopyran compounds | BEECHAM GROUP PLC (GB) | 1983-04-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387366-A1 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | GK, PSEN1, NEFM | ABCC9 895/4885ABCC8 818/4885KCNJ11 301/4885 |
| US-12564572-B2 | Topical ocular delivery of cromakalim | PRKCZ, GK, PHYKPL | ABCC9 1943/4885ABCC8 1197/4885KCNJ11 1088/4885 |
| US-20250108002-A1 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | PDE12, SYMPK, MYOC | ABCC9 1891/4885ABCC8 1831/4885KCNJ11 237/4885 |
| US-20260076961-A1 | COMBINATION TREATMENTS | SCNN1B, SCN2B, SCNN1A | ABCC9 255/4885ABCC8 314/4885KCNJ11 97/4885 |
| US-12564573-B2 | Topical ocular delivery of cromakalim | GK, PRKCZ, PHYKPL | ABCC9 2059/4885ABCC8 1046/4885KCNJ11 1324/4885 |
| US-20250108035-A1 | TOPICAL OCULAR DELIVERY OF CROMAKALIM | PDE12, SYMPK, MYOC | ABCC9 1891/4885ABCC8 1831/4885KCNJ11 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.